Aptamer-Functionalized, Ultra-Small, Monodisperse Silica Nanoconjugates for Targeted Dual-Modal Imaging of Lymph Nodes with Metastatic Tumors.

Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, 1304 W. Green Street, Urbana, IL, 61801 (USA).
Angewandte Chemie International Edition (Impact Factor: 11.34). 11/2012; DOI: 10.1002/anie.201205271
Source: PubMed

ABSTRACT A dual-modal imaging probe based on size-controlled silica nanoconjugates was synthesized for targeted imaging of lymph nodes by means of both PET and near infrared fluorescence techniques. 20 nm nanoconjugates functionalized with an aptamer (green triangles) that targets 4T1 breast cancer cells improved the detection efficiency of sentinel lymph nodes with metastatic tumors.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The sol-gel process provides a robust and versatile technology for the immobilization of biologicals. A wide range of inorganic, composites and hybrid materials can be prepared to encapsulate molecular drugs, proteins, antibodies/antigens, enzymes, nucleic acids, prokaryotic and eukaryotic cells into bulk gels, particles and films. This review describes the applications of sol-gel encapsulation relevant to medicinal chemistry focusing on the recent development of biosensors as well as systems for production, screening and delivery of bioactive compounds and biomaterials.
    Current Topics in Medicinal Chemistry 02/2015; 15(3):223-244. · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review highlights recent progress in developing DNA aptamers for personalized medicine, with more focus on in vivo studies for potential clinical applications. Examples include design of aptamers in combination with DNA nanostructures, nanomaterials, or microfluidic devices as diagnostic probes or therapeutic agents for cancers and other diseases. The use of aptamers as targeting agents in drug delivery is also covered. The advantages and future directions of such DNA aptamer-based technology for the continued development of personalized medicine are discussed.
    Current opinion in chemical engineering. 05/2014; 4:79-87.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range of factors including circulation time, interactions with the mononuclear phagocyte system, extravasation from circulation at the tumor site, targeting strategy, release from the delivery vehicle, and uptake in cancer cells. Nanotechnology provides the possibility of creating delivery systems where the design constraints are decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing tumor accumulation, and improving efficacy. The physico-chemical properties of nanoparticle-based delivery platforms introduce additional complexity associated with pharmacokinetics, tumor accumulation, and biodistribution. To assess the impact of nanoparticle-based delivery systems, we first review the design strategies and pharmacokinetics of FDA-approved nanomedicines. Next we review nanomedicines under development, summarizing the range of nanoparticle platforms, strategies for targeting, and pharmacokinetics. We show how the lack of uniformity in preclinical trials prevents systematic comparison and hence limits advances in the field.
    Frontiers in Chemistry 08/2014; 2:69.


Available from
May 22, 2014